Etentamig reported a significantly improved objective response rate (ORR) of 74% and a 60% reduction in risk of disease progression or death, with progression-free survival showing a hazard ratio of 0.40 versus investigator's choice of standard available therapies.
Etentamig reported a significantly improved objective response rate (ORR) of 74% and a 60% reduction in risk of disease progression or death, with progression-free survival showing a hazard ratio of 0.40 versus investigator's choice of standard available therapies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.55
